Moreover, the ability of TP53-small molecules inhibitor to synergize with conventional chemotherapeutic agents has been well established in other tumor types, as in leukemia, ovarian cancer, and non-small lung cancer [69,70,71], thus suggesting the possibility to reduce chemotherapeutic doses in clinical settings minimizing any potential side-effects in cancer patients [56]. The gene discussed is TP53; the disease is ovarian carcinoma.